首页> 外文OA文献 >Relugolix, A Novel Oral GnRH Receptor Antagonist, versus Leuprolide Depot for Prostate Cancer: The HERO Phase 3 Trial

【2h】

Relugolix, A Novel Oral GnRH Receptor Antagonist, versus Leuprolide Depot for Prostate Cancer: The HERO Phase 3 Trial

机译：Relugolix，一种新的口服Gnrh受体拮抗剂，与前列腺癌的Leuplolide Depot：英雄第3阶段试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
D.E. Spratt; N. Shore; A. Bossi; D. van Veenhuyzen; B. Selby; V. Kang; D. Dearnaley;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment [J] . Jialu Lv, Jianqing Lin Asian journal of andrology . 2021,第3期

机译：Relugolix作为前列腺癌治疗的有希望的新型口腔拮抗剂
2. Relugolix GnRH (LHRH) receptor antagonist Treatment of uterine fibroids Treatment of endometriosis-related pain Treatment of prostate cancer [J] . Elsharoud A., Ali M., Al-Hendy A. Drugs of the Future . 2019,第2期

机译：Relugolix GNRH（LHRH）受体拮抗剂治疗子宫肌瘤治疗子宫内膜异位症相关疼痛治疗前列腺癌
3. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. [J] . Tomera K, Gleason D, Gittelman M, The Journal of Urology . 2001,第5期

机译：促性腺激素释放激素拮抗剂abarelix药房与促黄体激素释放激素激动剂亮丙瑞林或戈舍瑞林：前列腺癌患者内分泌和生化功效的初步结果。
4. Proteome-wide drug dose-response of prostate cancer cell lines exposed to androgen receptor antagonist by microflow-LC SWATH MS analysis [C] . L.C. Gillet, S. Amon, Y. Uchida, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：通过Microflow-LC SWATH MS分析将前列腺癌细胞拮抗剂暴露于雄激素受体拮抗剂的前列腺癌细胞响应
5. Development of pan-antagonists of mutant androgen receptors associated with antiandrogen resistant prostate cancer. [D] . Pan, Hongmu. 2009

机译：与抗雄激素抵抗性前列腺癌有关的突变雄激素受体泛拮抗剂的发展。
6. Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment [O] . Jialu Lv, Jianqing Lin 2021

机译：Relugolix作为前列腺癌治疗的有前途的新型口服GNRH拮抗剂
7. Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males [O] . David B. MacLean, Hongliang Shi, Hélène M. Faessel, 2015

机译：医学阉割使用Investational Oral GNRH拮抗剂Tak-385（Relugolix）：1期健康男性研究
8. Estradiol Alters the Effectiveness of Gonadotropin-Releasing Hormone (GnRH) in Ovine Pituitary Cultures: GnRH Receptors versus Responsiveness to GnRH [R] . Laws, S. C., Webster, J. C., Miller, W. L. 1990

机译：雌二醇改变促性腺激素释放激素（GnRH）在绵羊垂体培养中的有效性：GnRH受体与对GnRH的反应

Relugolix, A Novel Oral GnRH Receptor Antagonist, versus Leuprolide Depot for Prostate Cancer: The HERO Phase 3 Trial

著录项

引文网络

相似文献

相关主题

期刊订阅